Glenmark Pharmaceuticals today said its group unit has received the approval from the British authority for marketing of a drug that is used in the treatment of restless legs syndrome.
Glenmark Generics Europe, the European subsidiary of Glenmark Generics received regulatory approval from the British Medicines and Healthcare products Regulatory Authority (MHRA)for Ropinirole film-coated tablets, it said in a statement to the Bombay Stock Exchange (BSE).
Moderate to severe idiopathic restless legs syndrome is typically represented by patients who suffer with insomnia or severe discomfort in the limbs.
The company has "commenced the marketing and distribution of this product in the British market for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome", it further said.
Besides, Glenmark Generics Europe has also began distributing Lercanidipine Hydrochloride film-coated tablets. The drug is indicated for the treatment of mild to moderate essential hypertension, the company added. Glenmark Generics is a subsidiary of Glenmark Pharma.
Shares of Glenmark settled at Rs 277.45, up 0.27 per cent on the BSE.
